Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
New breast cancer study findings have been reported by researchers at Thomas Jefferson University
June 18th, 2009
"Here we used die Met-1 cell line in an orthotopic transplantation model in FVB/N mice to dissect the role of the Cav-1(P132L) mutation in human breast cancer. Identical experiments were performed in parallel with wild-type Cav-1," scientists in the United States report. "Cav-1(P132L) up-regulated the expression of estrogen receptor-a as predicted, because only estrogen receptor-a-positive patients have been shown to harbor Cav-1(PI32L) mutations. in the context of primary tumor formation, Cav-1(P132L) behaved as a loss-of-function mutation, lacking any tumor suppressor activity. In contrast, Cav-1(PI32L) caused significant increases in cell migration, invasion, and...
Source: Women's Health Weekly (2009-06-18)
|
